<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02821286</url>
  </required_header>
  <id_info>
    <org_study_id>UZH</org_study_id>
    <nct_id>NCT02821286</nct_id>
  </id_info>
  <brief_title>Identification of Anaphylactogenic Antibodies in Peanut Allergy</brief_title>
  <official_title>Identification of Anaphylactogenic Antibodies in the Blood of Peanut Allergic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Children's Hospital, Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project intends the analysis and profiling of specific antibodies against major peanut&#xD;
      allergens in peanut allergic individuals and molecular cloning of human antibodies against&#xD;
      major peanut allergens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Characterization of patient samples reactivity (sera obtained from blood) against major&#xD;
           peanut allergens.&#xD;
&#xD;
        -  Isolation of antibody-producing B cells.&#xD;
&#xD;
        -  Molecular cloning of peanut-specific antibodies from antibody gene sequences obtained&#xD;
           from B cells.&#xD;
&#xD;
        -  Biophysical and functional characterization of isolated antibodies&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis and profiling of specific antibodies against major peanut allergens in samples derived from peanut allergic patients.</measure>
    <time_frame>June 2016 to May 2018</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peanut Allergy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <description>Blood sampling</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Full blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The project population includes patients of at least three years of age with a described&#xD;
        history of peanut allergy and/or sensitization to peanut allergens (as evidenced by&#xD;
        positive skin prick test or allergen-specific IgE testing).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants have a described clinical history of peanut allergy and/or are sensitized&#xD;
             to peanut allergens (as evidenced by positive skin prick test and allergen-specific&#xD;
             IgE testing)&#xD;
&#xD;
          -  Male and female subjects older than 3 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age below three years&#xD;
&#xD;
          -  patients suffering from any disease where blood withdrawals might impact the patients'&#xD;
             health status such as known anemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>November 15, 2020</last_update_submitted>
  <last_update_submitted_qc>November 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

